Kondo S - Search Results

1

Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents.

Takahashi H, Ikeda M, Kumada T, Osaki Y, Kondo S, Kusumoto S, Ohkawa K, Nadano S, Furuse J, Kudo M, Ito K, Yokoyama M, Okusaka T, Shimoyama M, Mizokami M. Takahashi H, et al. Among authors: kondo s. Hepatol Res. 2015 Dec;45(12):1220-7. doi: 10.1111/hepr.12496. Epub 2015 Mar 2. Hepatol Res. 2015. PMID: 25627550

2

Spontaneous regression of hepatocellular carcinoma.

Kondo S, Okusaka T, Ueno H, Ikeda M, Morizane C. Kondo S, et al. Int J Clin Oncol. 2006 Oct;11(5):407-11. doi: 10.1007/s10147-006-0591-4. Int J Clin Oncol. 2006. PMID: 17058140

3

Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?

Hashimoto K, Ueno H, Ikeda M, Kojima Y, Hagihara A, Kondo S, Morizane C, Okusaka T. Hashimoto K, et al. Among authors: kondo s. Oncology. 2009;77(3-4):217-23. doi: 10.1159/000236022. Epub 2009 Sep 4. Oncology. 2009. PMID: 19729980

4

Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.

Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, Tanaka T, Nakachi K, Mitsunaga S, Kojima Y, Hagihara A, Hiraoka N. Iwasa S, et al. Among authors: kondo s. Jpn J Clin Oncol. 2010 Apr;40(4):313-8. doi: 10.1093/jjco/hyp173. Epub 2010 Jan 4. Jpn J Clin Oncol. 2010. PMID: 20047862

5

[Chemotherapy].

Ikeda M, Nakachi K, Mitsunaga S, Ueno H, Morizane C, Kondo S, Okusaka T. Ikeda M, et al. Among authors: kondo s. Gan To Kagaku Ryoho. 2010 Mar;37(3):408-12. Gan To Kagaku Ryoho. 2010. PMID: 20332676 Review. Japanese.

6

Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.

Sugiyama E, Kaniwa N, Kim SR, Hasegawa R, Saito Y, Ueno H, Okusaka T, Ikeda M, Morizane C, Kondo S, Yamamoto N, Tamura T, Furuse J, Ishii H, Yoshida T, Saijo N, Sawada J. Sugiyama E, et al. Among authors: kondo s. Clin Pharmacokinet. 2010 Aug;49(8):549-58. doi: 10.2165/11532970-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20608756

7

[Hepatocellular carcinoma].

Kondo S, Ueno H, Morizane C, Okusaka T. Kondo S, et al. Gan To Kagaku Ryoho. 2010 Jul;37(7):1219-23. Gan To Kagaku Ryoho. 2010. PMID: 20647702 Japanese.

8

Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites.

Soeda A, Morita-Hoshi Y, Kaida M, Wakeda T, Yamaki Y, Kojima Y, Ueno H, Kondo S, Morizane C, Ikeda M, Okusaka T, Heike Y. Soeda A, et al. Among authors: kondo s. Jpn J Clin Oncol. 2010 Dec;40(12):1184-8. doi: 10.1093/jjco/hyq112. Epub 2010 Jul 22. Jpn J Clin Oncol. 2010. PMID: 20656693

9

Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases.

Suzuki E, Furuse J, Ikeda M, Okusaka T, Nakachi K, Mitsunaga S, Ueno H, Morizane C, Kondo S, Shimizu S, Kojima Y, Hagihara A. Suzuki E, et al. Among authors: kondo s. Oncology. 2010;79(1-2):39-45. doi: 10.1159/000318020. Epub 2010 Nov 10. Oncology. 2010. PMID: 21063134

10

Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.

Kaida M, Morita-Hoshi Y, Soeda A, Wakeda T, Yamaki Y, Kojima Y, Ueno H, Kondo S, Morizane C, Ikeda M, Okusaka T, Takaue Y, Heike Y. Kaida M, et al. Among authors: kondo s. J Immunother. 2011 Jan;34(1):92-9. doi: 10.1097/CJI.0b013e3181fb65b9. J Immunother. 2011. PMID: 21150717 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,709 results

Search Page

Filters